Price (delayed)
$3
Market cap
$16.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$9.85M
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN
There are no recent dividends present for LPCN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.